Cell Therapeutics shares fell 10.7 percent Monday after the Food and Drug Administration ordered it to stop enrolling patients in its clinical trial of a drug candidate for blood-related cancers.
The Seattle biotechnology company said the halt was prompted by the death of a patient from myocarditis, an inflammation of the heart muscle wall. The patient was over 70, and was being treated with the company’s drug Tosedostat in combination with another drug.
The FDA has requested more information on patients and adverse events in the clinical trial. Cell Therapeutics can’t enroll new patients until the agency gives the go-ahead.
Cell Therapeutics stock closed at $1.09 Monday, down 13 cents.
Most Read Business Stories
- 6 Dr. Seuss books won't be published for racist images
- Frontier cancels flight, citing maskless passengers
- Biden vows enough vaccine for all US adults by end of May
- Amazon sued by Black cloud-computing manager over alleged racial discrimination and sexual harassment
- Texas becomes biggest US state to lift COVID-19 mask mandate